IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

Código QR

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

The use of BRAF and MEK inhibitors for patients with BRAF-mutant melanoma is limited as patients relapse on treatment as quickly as 6 months due to acquired resistance. We generated trametinib and dabrafenib resistant melanoma (TDR) cell lines to the MEK and BRAF inhibitors, respectively. TDR cells...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hima Patel, Rosalin Mishra, Nour Yacoub, Samar Alanazi, Mary Kate Kilroy, Joan T. Garrett
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	melanoma BRAF resistance IGF1R IR Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/120f7fae924344028d8f89296f08696d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

BRAF Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters
por: Aris Spathis, et al.
Publicado: (2019)

Dermoscopic Features as Predictors of BRAF Mutational Status and Sentinel Lymph Node Positivity in Primary Cutaneous Melanoma
por: Nika Filipović, et al.
Publicado: (2021)

BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells
por: Prashant Karki, et al.
Publicado: (2021)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
por: Sandip Ganguly, et al.
Publicado: (2021)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Stefanie Hoyer, et al.
Publicado: (2021)

Melanoma Targeted Therapies beyond <i>BRAF</i>-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
por: Karam Khaddour, et al.
Publicado: (2021)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo MC, et al.
Publicado: (2021)

Relevance of BRAF Subcellular Localization and Its Interaction with <i>KRAS</i> and <i>KIT</i> Mutations in Skin Melanoma
por: Marius-Alexandru Beleaua, et al.
Publicado: (2021)

Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
por: Michael G. White, et al.
Publicado: (2021)

High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients
por: Wan-Ru Chao, et al.
Publicado: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
por: Yalikong A, et al.
Publicado: (2021)

Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl ester as ATP-competitive inhibitors of BRAF: A bioinformatics study
por: Vidhi Malik, et al.
Publicado: (2021)

Preliminary Study on the Relationship of BRAF Mutations with the Outcome of the First 131I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid Carcinoma
por: Shangguan L, et al.
Publicado: (2021)

Seven Synchronous Primary Melanomas on the Back
por: Sanja Javor, et al.
Publicado: (2021)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
por: Jennifer A. Silver, et al.
Publicado: (2021)

Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with <i>BRAF<sup>V600E</sup></i>-Mutant Advanced Papillary Thyroid Carcinoma
por: Eyun Song, et al.
Publicado: (2021)

Clinicopathological Significance of BRAF (V600E), NRAS (Q61K) and TERT (C228T, C250T and SNP Rs2853669) Mutations in Bulgarian Papillary Thyroid Carcinoma Patients
por: Vidinov K., et al.
Publicado: (2021)

Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification
por: Sara Moreno, et al.
Publicado: (2021)

Analysis of Increased EGFR and IGF-1R Signaling and Its Correlation with Socio-Epidemiological Features and Biological Profile in Breast Cancer Patients: A Study in Northern Brazil
por: Silva Rocha F, et al.
Publicado: (2021)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Shanique Alabi, et al.
Publicado: (2021)

Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets
por: Yinqi Zhang, et al.
Publicado: (2021)

Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case
por: Tian Yang, et al.
Publicado: (2021)

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
por: Qing Yin, et al.
Publicado: (2019)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Maria Gonzalez-Cao, et al.
Publicado: (2021)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Shahneen Sandhu, et al.
Publicado: (2021)

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
por: Shujun Han, et al.
Publicado: (2018)

PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
por: Gang Yang, et al.
Publicado: (2021)

IGF1 Gene Polymorphism in Selected Species of the Canidae Family
por: Jakubczak Andrzej, et al.
Publicado: (2017)

Genetic structure and population dynamics of autochthonous and modern porcine breeds. Analysis of the IGF2 and MC4R genes that determine carcass characteristics
por: Llambí,Silvia, et al.
Publicado: (2020)

Immunological Distribution of the Placental Lactogene and IGF-1 Receptor on Free-chorionic Villi of the Newborns Small for Gestational Age Placentae
por: Prieto,Ruth, et al.
Publicado: (2008)

Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
por: Shujun Han, et al.
Publicado: (2018)

Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved
por: Luis G. Guijarro, et al.
Publicado: (2021)

Post-Secular Identity? Developing a New Approach to Religion in International Relations and IR Studies
por: Joanna Kulska, et al.
Publicado: (2021)

Expression of genes encoding IGF1, IGF2, and IGFBPs in blood of obese adolescents with insulin resistance
por: Minchenko Dmytro O., et al.
Publicado: (2019)

KINETIC STUDY OF THE HYDROGENATION OF CITRAL ON Ir PROMOTED Au/TiO2 CATALYST
por: MARTÍNEZ,JOSÉ J, et al.
Publicado: (2013)

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
por: Yifei Qin, et al.
Publicado: (2021)

Association of selected polymorphic sites in the IGF1R gene with body weight and conformation of Hereford cattle
por: Małgorzata Anna Szewczuk, et al.
Publicado: (2020)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
por: Najla Fakhruddin, et al.
Publicado: (2017)

FRONTIER ORBITALS AND IR FREQUENCIES OF CYCLIC HYDROXAMIC ACIDS RELATED TO ANTIMICROBIAL ACTIVITY
por: BRAVO,HÉCTOR R, et al.
Publicado: (2001)